Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Christopher Ryan Sullivan net worth and biography

Christopher Sullivan Biography and Net Worth

CAO of Avalo Therapeutics

Mr. Sullivan most recently served as the Company’s Chief Accounting Officer and prior to that as Interim Chief Financial Officer, during which time the Company raised approximately $80 million in gross proceeds. Prior to joining Avalo, Mr. Sullivan was the Corporate Controller for Sucampo Pharmaceuticals, a Nasdaq-listed specialty pharmaceuticals company, when it was merged with Mallinckrodt in a $1.2 billion transaction. He also served as the Corporate Controller for OpGen, a Nasdaq-listed diagnostic company, and prior to that was a Senior Manager at Ernst & Young. Mr. Sullivan has a strong public company and life science background, including significant experience with equity and debt capital raises, acquisitions, divestitures, in and out-license transactions, enterprise resource planning implementations, and financial planning and analysis from leading finance and accounting functions at various public biotechnology, molecular diagnostic, and pharmaceutical companies. Mr. Sullivan received dual BS degrees in Finance and Accounting from the University of Maryland, College Park where he graduated magna cum laude, and he is a Certified Public Accountant.

What is Christopher Ryan Sullivan's net worth?: The estimated net worth of Christopher Ryan Sullivan is at least $69.20 as of June 9th, 2023. Mr. Sullivan owns 5 shares of Avalo Therapeutics stock worth more than $69 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Sullivan may own. Additionally, Mr. Sullivan receives a salary of $350,000.00 as CAO at Avalo Therapeutics. Learn More about Christopher Ryan Sullivan's net worth.
How old is Christopher Ryan Sullivan?: Mr. Sullivan is currently 40 years old. There are 3 older executives and no younger executives at Avalo Therapeutics. The oldest executive at Avalo Therapeutics is Dr. Solomon H. Snyder M.D., Founder and Chairman of Scientific Advisory Board, who is 85 years old. Learn More on Christopher Ryan Sullivan's age.
What is Christopher Ryan Sullivan's salary?: As the CAO of Avalo Therapeutics, Inc., Mr. Sullivan earns $350,000.00 per year. The highest earning executive at Avalo Therapeutics is Dr. Garry A. Neil M.D., Chairman of the Board, President & CEO, who commands a salary of $475,000.00 per year. Learn More on Christopher Ryan Sullivan's salary.
How do I contact Christopher Ryan Sullivan?: The corporate mailing address for Mr. Sullivan and other Avalo Therapeutics executives is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. Avalo Therapeutics can also be reached via phone at (410) 522-8707 and via email at [email protected]. Learn More on Christopher Ryan Sullivan's contact information.
Has Christopher Ryan Sullivan been buying or selling shares of Avalo Therapeutics?: Christopher Ryan Sullivan has not been actively trading shares of Avalo Therapeutics during the last ninety days. Most recently, on Friday, June 9th, Christopher Ryan Sullivan bought 2 shares of Avalo Therapeutics stock. The stock was acquired at an average cost of $820.80 per share, with a total value of $1,641.60. Following the completion of the transaction, the chief financial officer now directly owns 5 shares of the company's stock, valued at $4,104. Learn More on Christopher Ryan Sullivan's trading history.
Who are Avalo Therapeutics' active insiders?: Avalo Therapeutics' insider roster includes Schond Greenway (CFO), Christopher Sullivan (CAO), and H. Wilkins (Insider). Learn More on Avalo Therapeutics' active insiders.
Are insiders buying or selling shares of Avalo Therapeutics?: In the last year, Avalo Therapeutics insiders bought shares 16 times. They purchased a total of 315 shares worth more than $238,317.60. In the last year, insiders at the sold shares 1 times. They sold a total of 11,442 shares worth more than $1,675,108.80. The most recent insider tranaction occured on June, 26th when Major Shareholder Armistice Capital, Llc sold 11,442 shares worth more than $1,675,108.80. Insiders at Avalo Therapeutics own 0.2% of the company. Learn More about insider trades at Avalo Therapeutics.
Information on this page was last updated on 6/26/2023.

Christopher Ryan Sullivan Insider Trading History at Avalo Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/9/2023	Buy	2	$820.80	$1,641.60	5
12/10/2021	Buy	3	$376.80	$1,130.40

Christopher Ryan Sullivan Buying and Selling Activity at Avalo Therapeutics

Avalo Therapeutics Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Today's Range

Now: $13.84

$12.80

$13.96

50 Day Range

MA: $8.81

$4.20

$21.75

2 Week Range

Now: $13.84

$3.95

$1,130.40

Volume

18,101 shs

Average Volume

547,892 shs

Market Capitalization

$14.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Protect Your Bank Account Before It’s Too Late

From Weiss Ratings | Ad

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Christopher Sullivan Biography and Net Worth

What is Christopher Ryan Sullivan's net worth?

How old is Christopher Ryan Sullivan?

What is Christopher Ryan Sullivan's salary?

How do I contact Christopher Ryan Sullivan?

Has Christopher Ryan Sullivan been buying or selling shares of Avalo Therapeutics?

Who are Avalo Therapeutics' active insiders?

Are insiders buying or selling shares of Avalo Therapeutics?